COMMUNIQUÉ DE PRESSE

Quantum BioPharma Reports Its Unaudited Financial and Operational Results for the Third Quarter

Pune, India, November 18th, 2026, FinanceWire


On Nov. 13, 2026 Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders' equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025. Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026.

Third Quarter 2026 Financial Results

Quantum reduced operating expenses year over year while increasing total assets, cash holdings and shareholders' equity. Management has concluded that the Company's cash and cash equivalents and digital assets as of September 30, 2026 are sufficient to carry out its planned operations over the next twelve months.

Liquidity and Balance Sheet Strength

Cash and cash equivalents and digital assets totaled approximately US$12.22 million as of September 30, 2026, compared with US$4.12 million at December 31, 2025 (excluding US$1.60 million of restricted digital assets at that date). Cash and cash equivalents increased approximately 87% to US$3.56 million, from US$1.91 million at December 31, 2025. Digital assets increased approximately 127% to US$8.66 million, from US$3.82 million at December 31, 2025 (restricted and unrestricted). No digital assets were restricted as of September 30, 2026. Total shareholders' equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025. Total assets increased approximately 55% to US$17.33 million, from US$11.16 million at December 31, 2025. Working capital increased to approximately US$5.47 million as of September 30, 2026, compared with approximately US$0.42 million at December 31, 2025. Notes payable decreased to US$0.30 million, from US$1.30 million at December 31, 2025, following the repayment of US$1.00 million of the BitGo loan during the nine months ended September 30, 2026.

Key Financial Ratios (as of September 30, 2026)

Current ratio of 1.72 as of September 30, 2026, compared to 1.07 as of December 31, 2025. Debt-to-Equity ratio of 0.77 as of September 30, 2026, compared to 1.19 as of December 31, 2025. Total liabilities were approximately US$7.56 million as of September 30, 2026, compared with US$6.06 million at December 31, 2025. Approximately 38% of current liabilities as of September 30, 2026 are non-cash fair-value items, being US$2.17 million of warrant liabilities and US$0.68 million of derivative liabilities. Equity represented approximately 56% of total assets as of September 30, 2026, compared with 46% as of December 31, 2025.

Reduced Operating Expenses and Cash Use

Total operating expenses decreased approximately 24% in the third quarter of 2026, to US$3.56 million from US$4.68 million in the third quarter of 2025. For the nine months ended September 30, 2026, total operating expenses decreased approximately 32%, to US$8.81 million from US$12.93 million. Cash used in operating activities decreased approximately 21%, to US$6.25 million for the nine months ended September 30, 2026 from US$7.93 million for the comparable 2025 period. Net loss for the nine months ended September 30, 2026 was US$17.32 million, compared with US$23.25 million for the nine months ended September 30, 2025, a decrease of approximately 26%. The nine-month result includes an unrealized gain of US$0.64 million on the change in fair value of digital assets.

Third Quarter and Subsequent 2026 Corporate Highlights

Lucid-MS Phase 2 Trial: FDA Clearance and Study Start-Up Agreement with Thermo Fisher Scientific. On August 10, 2026, the Company announced that the FDA had cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the Company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis. Subsequent to quarter-end, on October 6, 2026, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 clinical trial of Lucid-MS, marking the initiation of formal study start-up activities. The trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of multiple sclerosis.

Unbuzzd

On September 24, 2026, Unbuzzd announced the appointment of Michael Zapolin as Chief Executive Officer, with a mandate that includes financing Unbuzzd, listing it on a stock exchange and executing a nationwide commercial rollout in the United States. Subsequent to quarter-end, on October 13, 2026, the Company and Unbuzzd extended the maturity of the Company's loan to Unbuzzd to December 31, 2027, and on October 15, 2026 the Company subscribed for 1,500,000 common shares of Unbuzzd at C$0.20 per share under Unbuzzd's private placement. Following the placement, the Company held a 19.87% ownership interest in Unbuzzd.

Management Commentary

"With FDA clearance in hand and our Study Start-Up Agreement signed with the clinical research business of Thermo Fisher Scientific, Lucid-MS has moved from planning into the implementation of its Phase 2 trial in progressive multiple sclerosis," said Zeeshan Saeed, Chief Executive Officer of Quantum.
"Shareholders' equity has grown 91% since the start of the year to US$9.77 million, and working capital now stands at US$5.47 million, while we reduced total operating expenses by 32% over the first nine months of 2026 compared with the same period last year," said Donal Carroll, Chief Financial Officer of Quantum.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.87% (as of November 12, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Other notable biopharmaceutical stocks include Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), Amgen Inc (NASDAQ: AMGN), Gilead Sciences, Inc (NASDAQ: GILD) and Pfizer Inc (NYSE:PFE)

Source: 

https://finance.yahoo.com/healthcare/articles/quantum-biopharma-achieve-91-increase-120500773.html

DISCLAIMER & COMPENSATION DISCLOSURE

This communication is a paid promotional investor awareness advertisement and should not be considered independent financial research, analyst coverage, or investment advice. USAStockReport.com and/or its parent, affiliate, or publishing entity Akchirpy Media LLP has received USD 750$ via wire transfer from FinnCom, Inc. for content creation, marketing, advertising, and distribution services relating to QNTM using publicly available information during the period of November 16th. No stock, options, warrants, or other securities compensation has been received. Quantum BioPharma Ltd. (QNTM) is an unaffiliated third party and did not commission, sponsor, review, or pay for this communication; the compensation described above was paid solely by FinnCom, Inc. Neither USAStockReport.com, Akchirpy Media LLP, nor any of their owners, employees, contractors, or affiliates are registered broker-dealers, investment advisers, or securities analysts with the U.S. Securities and Exchange Commission or any state securities regulator. Information contained in this communication is derived from publicly available sources, including SEC filings, company press releases, and public disclosures believed to be reliable; however, such information has not been independently verified by the publisher, and no representation or warranty is made regarding its accuracy, completeness, or timeliness. This communication should not be relied upon as a substitute for reviewing original source documents. Copies of SEC filings may be obtained free of charge from the SEC EDGAR database at www.sec.gov. This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and estimates and involve known and unknown risks and uncertainties that may cause actual results to differ materially. These risks include, without limitation, clinical trial outcomes, regulatory approval risks, financing risks, changing market conditions, competitive pressures, and other risks described in SEC filings. No obligation is undertaken to update forward-looking statements except as required by law. This communication is for informational advertising and investor awareness purposes only. Nothing contained herein constitutes investment advice, securities research, a recommendation to buy, sell, or hold any security, or legal, tax, accounting, or financial advice. Investing in securities involves substantial risk, including possible total loss of capital. Readers should conduct their own independent due diligence and consult qualified financial professionals before making any investment decision. This communication does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such offer or sale would be unlawful. The information contained in this article is derived exclusively from public press releases, SEC filings, and other official disclosures issued by Quantum BioPharma Ltd. No independent verification has been performed by the publisher. This content was provided for distribution by FinnCom, Inc., the compensating third party.



Contact
Editor
Ash K
UsaStockReport
editor@usastockreport.com


Disclaimer. This is a paid press release.